Jeffrey Hung
Stock Analyst at Morgan Stanley
(2.28)
# 2,614
Out of 4,886 analysts
207
Total ratings
40.34%
Success rate
-1.65%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey Hung
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGON CG Oncology | Maintains: Overweight | $52 → $56 | $25.98 | +115.55% | 4 | Jun 17, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Equal-Weight | $20 → $24 | $21.02 | +14.20% | 25 | May 20, 2025 | |
| CTNM Contineum Therapeutics | Maintains: Overweight | $25 → $20 | $3.90 | +412.82% | 3 | May 19, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $64 → $65 | $39.42 | +64.89% | 8 | May 9, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $183 → $166 | $109.13 | +52.11% | 6 | May 7, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Equal-Weight | $15 → $17 | $7.50 | +126.67% | 5 | May 6, 2025 | |
| ENGN enGene Holdings | Maintains: Overweight | $37 → $34 | $3.80 | +794.74% | 3 | Mar 11, 2025 | |
| RYTM Rhythm Pharmaceuticals | Assumes: Overweight | $72 | $65.14 | +10.53% | 11 | Mar 7, 2025 | |
| PTCT PTC Therapeutics | Assumes: Overweight | $67 → $70 | $47.63 | +46.97% | 11 | Mar 7, 2025 | |
| NBIX Neurocrine Biosciences | Assumes: Overweight | $185 → $150 | $128.74 | +16.51% | 26 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $4 | $1.47 | +173.04% | 3 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $85 | $52.99 | +60.41% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $38 → $35 | $7.34 | +376.84% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $27 | $13.61 | +98.38% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Underweight | $5 | $4.40 | +13.64% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $70 → $67 | $34.25 | +95.62% | 13 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $17 → $12 | $6.23 | +92.77% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $6.31 | +455.11% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $70 | $29.38 | +138.30% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $10 → $4 | $0.88 | +356.83% | 10 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $13 → $4 | $8.02 | -50.12% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $1 → $4 | $0.72 | +455.09% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $14 | $4.00 | +250.00% | 3 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $5 | $2.87 | +74.22% | 1 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $3 | $1.17 | +156.41% | 8 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $14 | $1.53 | +815.03% | 7 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $10 | $1.93 | +418.13% | 3 | Jan 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $23 → $22 | $43.51 | -49.43% | 10 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $146 → $149 | $13.94 | +965.28% | 2 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $100 → $60 | $1.76 | +3,309.09% | 5 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $6 | $3.18 | +88.68% | 9 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $58 → $54 | $0.46 | +11,713.61% | 6 | May 8, 2020 |
CG Oncology
Jun 17, 2025
Maintains: Overweight
Price Target: $52 → $56
Current: $25.98
Upside: +115.55%
ACADIA Pharmaceuticals
May 20, 2025
Maintains: Equal-Weight
Price Target: $20 → $24
Current: $21.02
Upside: +14.20%
Contineum Therapeutics
May 19, 2025
Maintains: Overweight
Price Target: $25 → $20
Current: $3.90
Upside: +412.82%
Ultragenyx Pharmaceutical
May 9, 2025
Maintains: Overweight
Price Target: $64 → $65
Current: $39.42
Upside: +64.89%
Jazz Pharmaceuticals
May 7, 2025
Maintains: Overweight
Price Target: $183 → $166
Current: $109.13
Upside: +52.11%
Bicycle Therapeutics
May 6, 2025
Maintains: Equal-Weight
Price Target: $15 → $17
Current: $7.50
Upside: +126.67%
enGene Holdings
Mar 11, 2025
Maintains: Overweight
Price Target: $37 → $34
Current: $3.80
Upside: +794.74%
Rhythm Pharmaceuticals
Mar 7, 2025
Assumes: Overweight
Price Target: $72
Current: $65.14
Upside: +10.53%
PTC Therapeutics
Mar 7, 2025
Assumes: Overweight
Price Target: $67 → $70
Current: $47.63
Upside: +46.97%
Neurocrine Biosciences
Mar 7, 2025
Assumes: Overweight
Price Target: $185 → $150
Current: $128.74
Upside: +16.51%
Mar 7, 2025
Assumes: Overweight
Price Target: $4
Current: $1.47
Upside: +173.04%
Mar 7, 2025
Assumes: Overweight
Price Target: $85
Current: $52.99
Upside: +60.41%
Mar 7, 2025
Assumes: Overweight
Price Target: $38 → $35
Current: $7.34
Upside: +376.84%
Mar 7, 2025
Assumes: Overweight
Price Target: $27
Current: $13.61
Upside: +98.38%
Mar 7, 2025
Assumes: Underweight
Price Target: $5
Current: $4.40
Upside: +13.64%
Feb 13, 2025
Upgrades: Overweight
Price Target: $70 → $67
Current: $34.25
Upside: +95.62%
Dec 13, 2024
Downgrades: Equal-Weight
Price Target: $17 → $12
Current: $6.23
Upside: +92.77%
Jul 26, 2024
Initiates: Overweight
Price Target: $35
Current: $6.31
Upside: +455.11%
May 23, 2024
Maintains: Overweight
Price Target: $50 → $70
Current: $29.38
Upside: +138.30%
Dec 19, 2023
Downgrades: Underweight
Price Target: $10 → $4
Current: $0.88
Upside: +356.83%
Dec 19, 2023
Downgrades: Underweight
Price Target: $13 → $4
Current: $8.02
Upside: -50.12%
Dec 19, 2023
Upgrades: Equal-Weight
Price Target: $1 → $4
Current: $0.72
Upside: +455.09%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $14
Current: $4.00
Upside: +250.00%
Jul 11, 2023
Reiterates: Equal-Weight
Price Target: $5
Current: $2.87
Upside: +74.22%
Mar 20, 2023
Maintains: Equal-Weight
Price Target: $9 → $3
Current: $1.17
Upside: +156.41%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $15 → $14
Current: $1.53
Upside: +815.03%
Jan 30, 2023
Downgrades: Underweight
Price Target: $50 → $10
Current: $1.93
Upside: +418.13%
Nov 2, 2022
Maintains: Equal-Weight
Price Target: $23 → $22
Current: $43.51
Upside: -49.43%
May 11, 2022
Maintains: Equal-Weight
Price Target: $146 → $149
Current: $13.94
Upside: +965.28%
Aug 13, 2021
Downgrades: Underweight
Price Target: $100 → $60
Current: $1.76
Upside: +3,309.09%
Apr 19, 2021
Maintains: Equal-Weight
Price Target: $7 → $6
Current: $3.18
Upside: +88.68%
May 8, 2020
Maintains: Overweight
Price Target: $58 → $54
Current: $0.46
Upside: +11,713.61%